Research and Markets: A Key Element of Mayne Pharma's New Strategy Is to Acquire Niche Marketed or Close-To-Market Proprietary Products in the Oncology Field.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46138) has announced the addition of Espicom Business Intelligence's Mayne Pharma Generics Company Intelligence Report to their offering. These generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA ANDA abbr. abbreviated new drug application approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . The easy and cost effective way to monitor developments in leading generic drug generic drug, a drug sold or prescribed under the nonproprietary name of its active ingredients or under a generally descriptive name rather than under a brand or trade name. industry players. Generics Company Reports are packed with facts, figures and statistics, providing you with the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such comprehensive insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry. Each report is updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether it's the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market. Use Generic Company Reports to: * Evaluate the competitive operating environment In computing, an operating environment is the environment in which users run programs, whether in a command line interface, such as in MS-DOS or the Unix shell, or in a graphical user interface, such as in the Macintosh operating system. . * Identify which companies are applying for ANDAs, and for what. * Understand generic companies' product line up. * Monitor the financial performance of leading generics players. * Track the twists and turns of litigation. Stay in touch with the latest M&A and strategic alliances Content Outline: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. PRODUCTS Innovative Product Distribution Deals Recent product approvals 4. FINANCIAL RESULTS Latest Yearly Results 5. MAJOR DEVELOPMENTS Mergers, acquisitions and agreements Litigation Mayne Pharma is one of the world's leading generic injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. drug manufacturers. Its principal manufacturing site is in Australia, although the company's head office is now in the UK. The company has other manufacturing sites in the USA, Germany and India. The company used to be part of the Mayne Group, which also undertakes drug wholesaling and provision of other health services health services Managed care The benefits covered under a health contract . Mayne Pharma was demerged in November 2005, and the remaining Mayne Group was renamed Symbion Healthcare. Sales for the six months ended December 2005 amounted to A$391.3 million. Of this, the Europe, Middle East & Africa region accounted for A$190.5 million, or 48.7% of the total. Sales in North America amounted to A$101.5 million The company has a number of collaborative agreements with companies around the world. IVAX IVAX Industrial Vax (Dec Computer) has various deals regarding the distribution of paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , one of Mayne's key products. A number of agreements have recently been signed with Indian companies, such as Orchid, Strides Arcolab and Zydus Cadila. Mayne is also involved in the distribution of innovative products. A key element of Mayne Pharma's new strategy is to acquire niche marketed or close-to-market proprietary products in the oncology field. Mayne is involved in the biosimilar field, through its 2005 distribution deal with Pliva. This currently covers only one product, however: G-CSF G-CSF granulocyte colony-stimulating factor. G-CSF granulocyte-colony stimulating factor. G-CSF Granulocyte colony-stimulating factor Molecular therapeutics A biological response modifier, the recombinant DNA form of , which should enter trials shortly. The original deal also included EPO EPO see erythropoietin. EPO Erythropoietin, see there , but this was dropped in 2006. For more information visit http://www.researchandmarkets.com/reports/c46138 |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion